Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CaDAnCe-302: BGB-16673 vs Investigator's Choice in CLL/SLL After BTK and BCL2 Inhibitors
jRCT2051250031Phase 3Recruiting
- Sponsor
- BeOne Medicines
- Start
- May 2025
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of catadegbrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by BeOne Medicines. Primary endpoint: Progression-free survival. Started May 2025; status: recruiting.
02
Drugs
catadegbrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on jRCT2051250031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250031.